TD-1211 for Opioid-Induced Constipation:
Theravance-discovered, multivalent, µ-opioid receptor neutral antagonist
Peripherally selective
Designed to normalize bowel movement frequency and quality
Once daily oral dosing
Disclosures:
Dr. Webster is a consultant to Theravance for the TD-1211 development program. In the last 12 months, Dr. Webster has received Honoraria / Travel Support from the following
companies:
Covidien Mallinckrodt
Medtronic
Nektar Therapeutics
Pfizer
Salix Pharmaceuticals
Theravance, Inc., is investigating TD-1211 as a potential new treatment option for OIC.
